Table 2 Sensitivity to Aurora inhibitors of the PC9-derived cell lines used in the study

From: AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy

Cell linea

Barasertib (AURKB) IC50 (μM)

Barasertib (AURKB) % Cells

Tozasertib (AURKA, AURKB) IC50 (μM)

Tozasertib (AURKA, AURKB) % Cells

S49076 (AURKB, AXL, MET, FGFR1) IC50 (μM)

S49076 (AURKB, AXL, MET, FGFR1) % Cells

PC9

12.7

52

0.7

44

>50

55

PC9-GR1

13.9

45

5.7

65

> 50

56

PC9-GR2

30.7

69

0.5

47

1.2

54

PC9-GR3

0.05

9

0.1

14

0.3

4

PC9-GR4

34.4

67

7.8

63

> 50

65

PC9-GR5

0.04

37

0.2

25

0.9

33

PC9-ER

0.06

20

0.2

35

0.3

3

PC9-GR1-AZD1

0.04

32

0.2

37

0.2

9

PC9-GR1-AZD2

0.03

12

0.05

14

0.3

8

PC9-GR1-AZD3

0.03

15

0.08

26

0.2

6

PC9-GR1-AZD4

0.03

10

0.1

16

0.3

7

PC9-GR4-AZD1

27.5

64

2.6

53

> 50

57

PC9-GR4-AZD2

23.2

55

4.6

50

0.4

31

H1975

> 50

83

28.8

84

22.1

76

  1. The H1975 cell line is also included. The targets of the drugs are indicated between parentheses. The IC50s and percentage of surviving cells at 1 µM inhibitor (in MTT assays) are indicated
  2. aIn italics, cells carrying the T790M mutation at allelic fractions > 1%
Back to article page